Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831493 · ClinicalTrials.gov registry record · Phase 1
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00831493: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00831493 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00831493, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1. To assess the efficacy of vorinostat + RT in patients with LAPC as estimated by median overall survival. 2. To determine the radiological response as assessed by regular computer tomography (CT) and/or dynamic contrast enhanced computer tomography (DCE-CT) among patients treated with vorinostat and RT. 3. To evaluate the occurrence of symptoms and correlate to disease progression and tolerance to treatment using the MD Anderson Symptom Inventory-Gastrointestinal Module (MDASI-GI) self-reporting tool. 4. To correlate serum cytokine levels with symptoms and treatment outcomes.
Primary Outcome
MTD is maximum dose at which 6 patients are treated and there is at most 1 patient with dose limiting toxicities (DLT). Toxicities graded according to the Common Terminology Criteria for Adverse events (CTCAE).
Interventions
- DRUG Vorinostat
- RADIATION Chemoradiation (Radiation Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Why NCT00831493 stopped before completion
NCT00831493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT00831493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00831493 about?
NCT00831493 is a clinical study titled "Vorinostat Plus Radiation Therapy in Pancreatic Cancer". Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreatic cancer (LAPC). Secondary Endpoints: 1. To assess the efficacy of vorinostat + RT in patients with LAPC as estimated by median overall survival. 2. To...
What is the current status of trial NCT00831493?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2009-05. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00831493?
The interventions under investigation include: Vorinostat (DRUG), Chemoradiation (Radiation Therapy) (RADIATION).
Who is sponsoring clinical trial NCT00831493?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00831493's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia